Zhaoke Ophthalmology Future Growth
Future criteria checks 2/6
Zhaoke Ophthalmology is forecast to grow revenue at 85.8% per annum.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
Pharmaceuticals earnings growth | 12.7% |
Revenue growth rate | 85.8% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 27 Mar 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 422 | N/A | N/A | N/A | 1 |
12/31/2025 | 150 | N/A | N/A | N/A | 1 |
12/31/2024 | 29 | N/A | N/A | N/A | 1 |
12/31/2023 | 19 | -385 | N/A | N/A | N/A |
9/30/2023 | 15 | -433 | N/A | N/A | N/A |
6/30/2023 | 11 | -480 | -438 | -367 | N/A |
3/31/2023 | 6 | -444 | -504 | -349 | N/A |
12/31/2022 | N/A | -407 | -570 | -331 | N/A |
9/30/2022 | N/A | -355 | -565 | -315 | N/A |
6/30/2022 | N/A | -303 | -561 | -299 | N/A |
3/31/2022 | N/A | -1,216 | -450 | -272 | N/A |
12/31/2021 | N/A | -2,130 | -340 | -245 | N/A |
9/30/2021 | N/A | -2,210 | -407 | -234 | N/A |
6/30/2021 | N/A | -2,648 | -363 | -162 | N/A |
3/31/2021 | N/A | -1,688 | -321 | -133 | N/A |
12/31/2020 | N/A | -727 | -279 | -103 | N/A |
9/30/2020 | N/A | -607 | -134 | -53 | N/A |
12/31/2019 | N/A | -122 | -81 | -55 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if 6622's forecast earnings growth is above the savings rate (2.2%).
Earnings vs Market: Insufficient data to determine if 6622's earnings are forecast to grow faster than the Hong Kong market
High Growth Earnings: Insufficient data to determine if 6622's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 6622's revenue (85.8% per year) is forecast to grow faster than the Hong Kong market (8.2% per year).
High Growth Revenue: 6622's revenue (85.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 6622's Return on Equity is forecast to be high in 3 years time